Free Trial

Protagenic Therapeutics (PTIX) Competitors

Protagenic Therapeutics logo
$0.42 +0.02 (+4.74%)
As of 10:54 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PTIX vs. FLGC, SNSE, IMNN, BGXX, AIM, HOTH, CRVO, WENA, RLMD, and CLDI

Should you be buying Protagenic Therapeutics stock or one of its competitors? The main competitors of Protagenic Therapeutics include Flora Growth (FLGC), Sensei Biotherapeutics (SNSE), Imunon (IMNN), Bright Green (BGXX), AIM ImmunoTech (AIM), Hoth Therapeutics (HOTH), CervoMed (CRVO), ANEW Medical (WENA), Relmada Therapeutics (RLMD), and Calidi Biotherapeutics (CLDI). These companies are all part of the "pharmaceutical products" industry.

Protagenic Therapeutics vs.

Flora Growth (NASDAQ:FLGC) and Protagenic Therapeutics (NASDAQ:PTIX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and community ranking.

Protagenic Therapeutics has lower revenue, but higher earnings than Flora Growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Flora Growth$76.07M0.18-$57.04MN/AN/A
Protagenic TherapeuticsN/AN/A-$5M-$1.27-0.33

In the previous week, Flora Growth's average media sentiment score of 0.00 equaled Protagenic Therapeutics'average media sentiment score.

Company Overall Sentiment
Flora Growth Neutral
Protagenic Therapeutics Neutral

Flora Growth has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500. Comparatively, Protagenic Therapeutics has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500.

Flora Growth received 15 more outperform votes than Protagenic Therapeutics when rated by MarketBeat users.

CompanyUnderperformOutperform
Flora GrowthOutperform Votes
15
60.00%
Underperform Votes
10
40.00%
Protagenic TherapeuticsN/AN/A

Flora Growth presently has a consensus price target of $5.00, indicating a potential upside of 426.32%. Given Flora Growth's stronger consensus rating and higher probable upside, analysts clearly believe Flora Growth is more favorable than Protagenic Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Flora Growth
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Protagenic Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

36.0% of Flora Growth shares are owned by institutional investors. Comparatively, 8.0% of Protagenic Therapeutics shares are owned by institutional investors. 13.0% of Flora Growth shares are owned by insiders. Comparatively, 35.0% of Protagenic Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Protagenic Therapeutics has a net margin of 0.00% compared to Flora Growth's net margin of -30.99%. Flora Growth's return on equity of -268.17% beat Protagenic Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Flora Growth-30.99% -268.17% -57.51%
Protagenic Therapeutics N/A -308.97%-228.73%

Summary

Flora Growth beats Protagenic Therapeutics on 9 of the 12 factors compared between the two stocks.

Get Protagenic Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PTIX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PTIX vs. The Competition

MetricProtagenic TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$3.04M$6.56B$5.40B$9.25B
Dividend YieldN/A2.96%5.37%3.99%
P/E Ratio-0.339.4787.0317.58
Price / SalesN/A332.781,267.8378.99
Price / CashN/A64.1243.6036.96
Price / Book0.515.094.984.70
Net Income-$5M$154.90M$117.89M$224.57M
7 Day Performance-8.58%1.39%1.93%1.76%
1 Month Performance-30.01%1.56%3.88%5.37%
1 Year Performance-53.85%4.47%26.45%21.59%

Protagenic Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PTIX
Protagenic Therapeutics
0.4838 of 5 stars
$0.42
+4.7%
N/A-53.9%$3.04MN/A-0.332
FLGC
Flora Growth
2.1247 of 5 stars
$0.93
-3.2%
$5.00
+438.2%
-45.0%$13.40M$64.15M0.00280
SNSE
Sensei Biotherapeutics
4.2726 of 5 stars
$0.53
+3.5%
$4.33
+717.0%
-33.1%$13.34MN/A-0.4540
IMNN
Imunon
1.9295 of 5 stars
$0.92
+1.8%
$20.50
+2,137.7%
+57.3%$13.28M$500,000.00-0.4830
BGXX
Bright Green
N/A$0.07
+1.0%
N/A-66.7%$13.19MN/A-1.152
AIM
AIM ImmunoTech
1.8103 of 5 stars
$0.20
-4.7%
$2.75
+1,242.1%
-47.8%$13.07M$190,000.00-0.4420
HOTH
Hoth Therapeutics
2.3439 of 5 stars
$1.89
-0.5%
$4.00
+111.6%
+10.1%$13.05MN/A-1.434Gap Down
CRVO
CervoMed
3.0472 of 5 stars
$2.04
-3.3%
$42.00
+1,958.8%
-76.6%$12.59M$7.14M0.004News Coverage
Positive News
WENA
ANEW Medical
N/A$0.73
-0.5%
N/AN/A$12.51MN/A0.00N/AGap Up
RLMD
Relmada Therapeutics
4.0483 of 5 stars
$0.40
-2.0%
$4.25
+952.0%
-89.2%$12.19MN/A-0.1410Gap Up
CLDI
Calidi Biotherapeutics
3.0256 of 5 stars
$0.92
+0.4%
$16.67
+1,714.0%
N/A$12.02M$50,000.000.0038

Related Companies and Tools


This page (NASDAQ:PTIX) was last updated on 1/22/2025 by MarketBeat.com Staff
From Our Partners